Clinical Trial Update: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Docetaxel 75 mg/m2 every 3 weeks versus 50 mg/m2 every 2 weeks, in combination with darolutamide and androgen deprivation therapy, for m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Darolutamide (darolutamide)

Snippet

Sponsor: Jena University Hospital | Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING